Table 9 Three-year PFS, OS, DMFS, LRFS based on different IC regimens in IVa-b patients of EBV ≥ 1500 copies/ml
TPF (%) n = 326 | PF (%) n = 127 | TP (%) n = 68 | P value | |
|---|---|---|---|---|
Progression-free survival | ||||
Failures | 46(14.1%) | 42(33.0%) | 22 (32.4%) | < 0.001 |
Rate at 3 years | 81.5% (75.6–87.4) | 67.6% (58.2–77.0) | 57.3%(41.0–73.6) | |
Overall survival | ||||
Deaths | 10(3.1%) | 19 (15.0%) | 5(7.3%) | 0.029 |
Rate at 3 years | 97.3% (94.8–99.8) | 86.6%(79.7–93.5) | 85.8%(69.7–102) | |
Locoregional relapse-free survival | ||||
Locoregional failure | 15(4.6%) | 19 (15.0%) | 7 (10.3%) | 0.032 |
Rate at 3 years | 93.7% (90.0–97.4) | 85.7%(78.6–92.8) | 78.8%(59.0–98.6) | |
Distant metastasis-free survival | ||||
Distant failures | 31(9.5%) | 28 (22.0%) | 14 (20.6%) | 0.003 |
Rate at 3 years | 86.8% (81.9–91.7) | 78.0%(69.8–86.2) | 67.1%(49.9–84.3) | |